FDA Adverse Event Injury Summary report: N

GMK-SPHERE FEMORAL COMPONENT SPHERE CEMENTED SIZE 4

MDR report key: 8591157 · Received May 8, 2019

Report

Report Number
3005180920-2019-00348
Event Type
Injury
Date Received
May 8, 2019
Date of Event
April 8, 2019
Report Date
May 8, 2019
Manufacturer
MEDACTA INTERNATIONAL SA
Product Code
JWH
UDI-DI
07630030862403
PMA / PMN Number
K140826
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 1

BATCH REVIEW PERFORMED ON 06 MAY 2019: LOT 180351: (B)(4) ITEMS MANUFACTURED AND RELEASED ON 22-MAY-2018. EXPIRATION DATE: 2023-05-07. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, (B)(4) ITEMS OF THE SAME LOT HAVE BEEN ALREADY SOLD WITHOUT ANY SIMILAR REPORTED EVENT. ADDITIONAL IMPLANTS INVOLVED IN THE EVENT GMK-SPHERE 02.12.T3I4R TIBIAL TRAY FIXED CEMENTED SIZE T3-I4 R (K121416), LOT 180974: (B)(4) ITEMS MANUFACTURED AND RELEASED ON 13-JUN-2018. EXPIRATION DATE: 2023-05-31. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, (B)(4) ITEMS OF THE SAME LOT HAVE BEEN ALREADY SOLD WITHOUT ANY SIMILAR REPORTED EVENT. GMK-SPHERE 02.12.0411FR TIBIAL INSERT FIXED SPHERE FLEX SIZE 4/11 MM R (K140826), LOT 181898: (B)(4) ITEMS MANUFACTURED AND RELEASED ON 13-JUN-2018. EXPIRATION DATE: 2023-05-31. NO ANOMALIES FOUND RELATED TO THE PROBLEM. TO DATE, (B)(4) ITEMS OF THE SAME LOT HAVE BEEN ALREADY SOLD WITHOUT ANY SIMILAR REPORTED EVENT.

Description of Event or Problem · 1

THE PATIENT CAME IN, 6 MONTHS AFTER PRIMARY SURGERY, COMPLAINING OF PAIN AND INSTABILITY CAUSED BY A CONNECTIVE TISSUE DISORDER. THE SURGEON REVISED THE GMK SPHERE FEMORAL COMPONENT, LINER AND TIBIAL TRAY WITH A GMK HINGE FEMORAL COMPONENT, LINER AND TIBIAL TRAY. THE SURGERY WAS COMPLETED SUCCESSFULLY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
384898 GMK-SPHERE FEMORAL COMPONENT SPHERE CEMENTED SIZE 4 KNEE FEMORAL COMPONENT CEMENTED JWH MEDACTA INTERNATIONAL SA 180351 07630030862403

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention